<DOC>
	<DOC>NCT02238197</DOC>
	<brief_summary>To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Patients of both genders, older than 40 years,who suffer from chronic obstructive Pulmonary disease Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® 500µg/2ml Inhalation Solution Patients who exhibited adverse drug reactions</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>